New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
In the study, patients who underwent total knee arthroplasty (TKA) received identical pre-, intra- and postoperative pain management protocols, with the exception of 527 patients who received EXPAREL infiltration in place of a femoral nerve block ([FNB] n=583). The poster’s authors compared several patient and cost-related outcomes. Opioid use during hospitalization was significantly reduced in the EXPAREL group, other key findings included:
- Shorter hospital length of stay (2.93 days for the EXPAREL group vs. 3.19 days for FNB group, P<0.001)
- Lower 30-day all-cause readmission rate (0.95% for the EXPAREL group vs. 2.57% for the FNB group, P=0.041)
- Reduced inpatient fall rate (0.56% for the EXPAREL group vs. 2.11% for the FNB group, P=0.03)
- Increased rate of discharge to home (77.8% for the EXPAREL group vs. 72.21% for the FNB group, P=0.032)
“Based on our analysis, incorporating liposomal bupivacaine into the postsurgical analgesic protocol following total knee arthroplasty has significant and quantifiable benefits to both the patient and the institution,” said
“Dr. Iorio’s analysis is a best-in-class example of how an institution can effectively evaluate the value of a new pain modality, such as EXPAREL,” said
EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.
About EXPAREL®
EXPAREL (bupivacaine liposome injectable suspension) is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with up to a 45 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
About Pacira
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, including nerve block, oral surgery and chronic pain, as well as pediatrics, and the timing and success of any related clinical trials; the related timing and success of a
Company Contact:Pacira Pharmaceuticals, Inc. Jessica Cho , (973) 254-3574 Media Contact:Pure Communications, Inc. Dan Budwick , (973) 271-6085